Literature DB >> 812603

Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys.

S W Stadnicki, R W Fleischman, U Schaeppi, P Merriam.   

Abstract

Ototoxicity and general toxicity of cis-dichlorodiammineplatinum (ii), a compound with antitumor activity, were evaluated in four rhesus monkeys. Audiometry was performed with shock avoidance to donditioned stimuli of pure tones at frequencies from 0.25 to 18 kHz. Histopathologic lesions of the inner ear were identified with phase-contrast microscopy of surface preparations from the organ of Corti. The monkeys were also submitted to physical examinations, hematologic and blood chemical determinations, necropsies, and histopathologic evaluations. Cis-dichlorodiammineplatinum (II) was injected intravenously in one monkey in five daily doses of 1.25 mg/kg (LD50) and in three monkeys in ten to 26 doses of 0.625 mg/kg five times per week. Transient hearing loss occurred in the monkey treated with the largest dose and in one of the three animals treated at the lower dose. In both monkeys apparently normal hearing reappeared after 120 and 200 days. No hearing loss was detectable in the other two animals. All four monkeys, however, had loss of hair cells in the organ of Corti and lesions were most severe among the outer hair cells of the lower turns. Other effects in all four monkeys included severe chronic glomerulonephritis with intermittent azotemia. Two monkeys (positive controls) injected intramuscularly with ten or 25 daily doses of neomycin sulfate (50 mg/kg) responded with delayed permanent hearing loss that appeared 3 months after the start of treatment. Deafness was substantiated by a total loss of inner hair cells in the upper turns, by a severe loss in the lower turns, and by a moderate or severe loss of outer hair cells in the lower turns. The above observations indicated that cis-dichlorodiammineplatinum (II), at a treatment regimen which caused more severe organ toxicity, caused less severe ototoxicity than neomycin sulfate and destroyed hair cells at different sites than neomycin sulfate.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 812603

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  16 in total

1.  Effects of hyperbaric oxygen treatment on auditory hair cells after acute noise damage.

Authors:  Gleice Cristina Colombari; Maria Rossato; Omar Feres; Miguel Angelo Hyppolito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-21       Impact factor: 2.503

2.  Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer.

Authors:  Süleyman Yilmaz; Fatih Oktem; Emin Karaman
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-28       Impact factor: 2.503

3.  Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line.

Authors:  Yoshinobu Hirose; Julian A Simon; Henry C Ou
Journal:  J Assoc Res Otolaryngol       Date:  2011-07-06

4.  Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Tejbeer Kaur; Kelly E Sheehan; Vickram Ramkumar; Leonard P Rybak
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

5.  Resistin increases cisplatin-induced cytotoxicity in lung adenocarcinoma A549 cells via a mitochondria-mediated pathway.

Authors:  Wei-Jing Gong; Tao Zhou; Jia-Qiang Xu; Yi-Fei Huang; Li-Ping Xiang; Fang Zeng; Yong Han; Yong-Ning Lv; Yu Zhang; San-Lan Wu
Journal:  Med Oncol       Date:  2021-04-30       Impact factor: 3.064

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

7.  Changes in the stria vascularis of the guinea pig due to cis-platinum.

Authors:  R A Tange; V D Vuzevski
Journal:  Arch Otorhinolaryngol       Date:  1984

8.  Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II.

Authors:  R Becher; P Schütt; R Osieka; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 9.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

10.  Characteristics and drug responses of cochlear and vestibular adenylate cyclase.

Authors:  D Bagger-Sjöbäck; C S Filipek; J Schacht
Journal:  Arch Otorhinolaryngol       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.